View Clinical Trial (Medical Research Study)

Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response? - NCT01086358-44195(Clinical Trial 568040)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Cleveland
State:  
OH
Zip Code: 44195
Conditions: Workplace Migraine Treatment
Purpose: Researchers want to learn about work productivity after treatment of a migraine headache with your usual migraine medication as compared to your work productivity after treatment with Treximet. During this research subjects will take Treximet to treat 3 workday migraine attacks. For a second part of the research subjects will take their usual prescribed medication for 3 workday migraine attacks. The subjects will complete questionnaires after treating each migraine.
Study summary: A subject who is identified for study participation will participate in the screening and enrollment visit which determines the migraine treatment arm to which the subject will be randomized first. The subject will have a physical exam, vital signs recorded, health and medication questions asked, questionnaires completed and a headache diary explained and dispensed to the subject. If the subject is randomized to the Treximet treatment arm during the first part of the study, Treximet will be dispensed for use in treating workday migraines. The subject will call the study coordinator after treating a workday migraine and will report information about the migraine to the coordinator. When the subject has treated and reported on 3 migraines, the interim visit will be scheduled. The subject will bring the study diary and Treximet containers (if this was the arm the subject completed)to this visit. The subject will be asked about adverse events and medication changes as well as confirmation and review of the completed questionnaires and diaries from the prior weeks of study participation. The subject will be given new diaries and questionnaires (and Treximet to use if usual prescribed triptan was the treatment in the first arm) and repeat the activities to treat 3 more workday migraines. When the subject has notified the study coordinator about treating the 3rd workday migraine in this part of the study, the subject will be scheduled for the final study visit. The subject will bring the completed migraine diaries, completed questionnaires (and Treximet bottles if used during this arm) to the study visit. The subject will have the diaries and questionnaires reviewed, be asked about adverse events and medication changes and complete the final study questinnaires at this visit.
Criteria: Inclusion Criteria: - episodic migraine diagnosis - age 18 or older - currently using a triptan as primary migraine monotherapy - currently employed - if of childbearing potential, willing to prevent pregnancy during study participation - able to understand and consent to study participation Exclusion Criteria: - younger than age 18 - not having episodic migraine diagnosis - not using a triptan as primary migraine monotherapy - not currently employed - pregnant or nursing or unwilling to prevent pregnancy during study participation - unable to understand and consent to study participation
Study is available at: Cleveland Clinic, 9500 Euclid Avenue, T-33
Cleveland, OH 44195
United States

Primary Contact:
Stewart J Tepper, MD
Email: teppers@ccf.org
Phone: 216-636-5549

Secondary Contact:
Stewart J Tepper, MD
Email: teppers@ccf.org
Phone: 216/636-5549
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.